Pediatrics · LP-017
Cefixime Powder for oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-017Pediatrics
- Generic identity
- CefiximePowder for oral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-017
- Generic identity
- Cefixime
- Presentation
- Powder for oral suspension
- Catalogue strength
- 100 mg/5 mL
- Catalogue pack
- Bottle for reconstitution 30 mL / 60 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cefixime.
- Dosage form: powder for oral suspension.
- Catalogue concentration after reconstitution: 100 mg/5 mL.
- Catalogue final-volume options: 30 mL and 60 mL.
- Catalogue category: Pediatrics; navigation placement is not age authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Exact cefixime chemical form/basis, excipients and powder quantity before reconstitution.
- Water volume, reconstitution steps, shaking instructions, measuring device and after-reconstitution storage/discard period.
- Approved indication and age/weight eligibility for this exact product/jurisdiction.
- Whether both final-volume options are controlled/registered SKUs, plus shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution to 30 mL final volume | Reconstitution procedure, age eligibility and controlled SKU evidence are not supplied. |
| B | 100 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution to 60 mL final volume | Reconstitution procedure, age eligibility and controlled SKU evidence are not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cefixime is an oral cephalosporin antibiotic for selected infections caused by susceptible bacteria. Its oral forms include tablets and suspension presentations, but pharmaceutical equivalence should not be inferred from the ingredient name alone. The infection, local resistance situation and authorized product information determine appropriate use. This educational profile describes cefixime generally and does not constitute a Luang Pharma indication, registration claim or statement of therapeutic equivalence.
Clinical context and therapeutic role
Professional selection requires attention to the suspected pathogen, microbiological evidence when available, and the most appropriate antibiotic for the diagnosis. A broad-spectrum classification is not a reason to use it for uncomplicated viral symptoms. Tablet and suspension presentations may have different product-specific recommendations, so any switch needs confirmation. A clinical review should address beta-lactam allergy, kidney function, concomitant medicines and the plan for assessing treatment response.
Selected safety context
Diarrhoea, nausea and abdominal discomfort may occur. Severe allergic reactions, serious skin reactions and antibiotic-associated colitis are important risks. A history of cephalosporin or penicillin reactions requires careful evaluation rather than an assumption that another beta-lactam is safe. Kidney disease can affect treatment decisions. New bleeding, severe persistent diarrhoea, jaundice, breathing difficulty or facial swelling needs medical assessment. Do not change between formulations solely by comparing the number of milligrams.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This presentation is a powder intended to become an oral suspension after product-specific reconstitution. The stated concentration should be interpreted using the registered label, including the final volume. Water volume, preparation method and excipients require confirmation; another product’s instructions cannot be used as a substitute.
Reconstitution should follow the exact supplied instructions and appropriate pharmacy practice. Record the relevant preparation information and use the correct oral measuring device. Check the authorized storage conditions and period after reconstitution; no universal refrigeration rule or discard interval is assumed.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification/formula and powder-fill specification.
Approved label/leaflet with exact reconstitution, measuring and after-reconstitution handling instructions.
Bottle/closure/measuring-device specification and final-volume SKU matrix.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Cefixime powder for suspension — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 14 February 2024; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Cefixime tablet — official US label exampleArchived source classification: US official drug label example | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-017.
Professional enquiries
Request product-specific evidence for LP-017.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.